MiNK Therapeutics, shared a post by Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, adding:
“UPCOMING for MiNK Therapeutics: Three catalysts in three weeks:
- AACR2026 (Apr 20) → Phase II in PD-1 r/r gastroesophageal cancer (GEJ)
presenting from Memorial Sloan Kettering Cancer Center Drs. Sam Cytryn, Yelena Janjigian (Chief of GI Oncology, Memorial Sloan Kettering Cancer Center; OncoDaily Top 100) and others…. - ASGCT2026 (May 11–15) → new clinical findings in cancer and pulmonary diseases with experts Dr. Terese C. Hammond, MD
- ATS2026 (May 20) → INKT clinical activity in critical pulmonary diseases with MiNK Therapeutics, ImmunityBio, Inc. and Drs. Terese C. Hammond, MD, Jennifer S. Buell, Patrick Soon-Shiong, Lennie Sender, Marco Purbhoo, Mark A. Exley, Thiago Favano, Pharm D, MBA, Nils Rudqvist”
Quoting Jennifer S. Buell‘s post:
“MiNK Therapeutics: Three weeks. Three catalysts. INKT platform.
Over the next several weeks, MiNK will present across three major scientific forums:
- AACR2026 (Apr 20) – Phase II data in PD-1 refractory gastroesophageal cancer
- ASGCT2026 (May 11–15) – Mechanistic insights in cancer and pulmonary disease
- ATS2026 (May 20) – Expansion of our pulmonary disease activity
What’s emerging is a consistent theme:
agenT-797—shows important immune modulation across disease states From oncology to pulmonary disease (Keystone 2026), we are seeing critical foundation of clinical activity partner with the mechanism in patients who urgently need treatment options (pulmonary immune diseases and cancer)”